MT Newswires
Dianthus, Partner Say First Subject Dosed in Phase 1 Trial of Autoimmune Disease Treatment; Shares Up Pre-Bell
➖
AI Sentiment
Neutral
5/10
- Home
- DNTH
as of 12-26-2025 10:53am EST
$42.59
$0.56
-1.30%
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.8B | IPO Year: | N/A |
| Target Price: | $68.00 | AVG Volume (30 days): | 678.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.37 - $45.45 | Next Earning Date: | 11-05-2025 |
| Revenue: | $3,078,000 | Revenue Growth: | -42.64% |
| Revenue Growth (this year): | -65.12% | Revenue Growth (next year): | -31.95% |
AI-Powered DNTH Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 72.73%
72.73%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Dianthus Therapeutics Inc. News
DNTH Breaking Stock News: Dive into DNTH Ticker-Specific Updates for Smart Investing
GlobeNewswire
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
📈
AI Sentiment
Highly Positive
9/10
Compare DNTH vs Leading Stocks
See how DNTH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DNTH Dianthus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.